Annual Report 2025: Scaling Up to Amplify Our Impact
9 July 2026
Discover the 2025 Annual Report online.
The year 2025 marks a major milestone in the history of Laboratoires Pierre Fabre. Following three years of transformation driven by the Conquête 2025 strategic plan, the Group has reached a new scale and confirms its ambition to become a leading global player in precision oncology, medical dermatology, and dermo-cosmetics.
With sales of €3.2 billion, up 4.6%, a presence in 130 territories, and 71% of revenue generated internationally, Laboratoires Pierre Fabre continues its growth trajectory while remaining true to its purpose: caring for patients, consumers, and the most vulnerable communities.
This step-change is reflected in:
- A strengthened leadership position in precision oncology, now the Group’s primary growth driver.
- An increasingly medical and innovative dermo-cosmetics business, with 56 innovations launched in 2025.
- Strong international expansion, particularly across the Americas and Asia.
- Record investments in Research & Development, with €250 million invested in 2025.
- Industrial excellence supporting both healthcare sovereignty and decarbonization efforts.
- The daily commitment of 10,000 employees dedicated to serving patients and consumers.
- A strong commitment to sustainability, supported by a unique shareholder model through our Foundation and a recognized CSR strategy.
Over the past few years, we have demonstrated our ability to pioneer new ways of caring for people by leveraging our dual expertise in pharmaceuticals and dermo-cosmetics. We have reached a new scale and built solid foundations to further expand our impact on patients and consumers around the world.